Combining spirometry and fractional exhaled nitric oxide improves diagnostic accuracy for childhood asthma

2019 ◽  
Vol 14 (1) ◽  
pp. 21-28
Author(s):  
Sang‐Yong Eom ◽  
Joon Kee Lee ◽  
Young‐Joon Lee ◽  
Youn‐Soo Hahn
2018 ◽  
Vol 93 (2) ◽  
pp. 191-198 ◽  
Author(s):  
Zhen Wang ◽  
Paolo T. Pianosi ◽  
Karina A. Keogh ◽  
Feras Zaiem ◽  
Mouaz Alsawas ◽  
...  

2016 ◽  
Vol 51 (3) ◽  
pp. 316-328 ◽  
Author(s):  
Tim Gomersal ◽  
Sue Harnan ◽  
Munira Essat ◽  
Paul Tappenden ◽  
Ruth Wong ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e045420
Author(s):  
Christina Kellerer ◽  
Alexander Hapfelmeier ◽  
Rudolf A Jörres ◽  
Konrad Schultz ◽  
Benjamin Brunn ◽  
...  

IntroductionThe measurement of fractional exhaled nitric oxide (FeNO) is promising for diagnosing asthma and might substitute for bronchial provocation (BP) tests. To evaluate the diagnostic accuracy of FeNO within a confirmatory study, the following hypotheses will be tested: (1) A FeNO cut-off >50 ppb (parts per billion) is suitable for diagnosing asthma (sensitivity 35%, specificity 95%); (2) If the clinical symptoms ‘allergic rhinitis’ and ‘wheezing’ are present, asthma can be diagnosed at FeNO >33 ppb with a positive predictive value (PPV) >70% and (3) A FeNO >33 ppb can predict responsiveness to inhaled corticosteroid (ICS) with a PPV >70%.Methods and analysisA prospective diagnostic study will be conducted in three practices of pneumologists in Germany. 300 patients suspected of suffering from asthma will be included. As an index test, patients perform FeNO measurement with the device NIOX VERO. As reference a test, patients are examined with whole bodyplethysmography and BP, if necessary. After 3 months, patients with an asthma diagnosis will be examined again to verify the diagnosis and evaluate ICS responsiveness. Patients who did not receive an asthma diagnosis at the initial examination will be phoned after 3 months and asked about persistent respiratory symptoms to exclude false negative findings. As a primary target, sensitivity and specificity of FeNO >50 ppb will be determined. As a secondary target the PPV for asthma at FeNO >33 ppb, when the symptoms ‘allergic rhinitis’ and ‘wheezing’ are present, will be calculated. Regarding ICS responsiveness, the PPV of FeNO >33 ppb will be determined.Ethics and disseminationThe study was approved by the Ethical Committee of the Technical University of Munich (Reference number 122/20 S). The major results will be published in peer-reviewed academic journals and disseminated through conferences.Trial registration numberDRKS00021125.


Sign in / Sign up

Export Citation Format

Share Document